---
figid: PMC4632748__ijms-16-24243-g003
figlink: /pmc/articles/PMC4632748/figure/ijms-16-24243-f003/
number: F3
caption: 'The tamoxifen pathway and possible mechanisms of endocrine resistance in
  breast cancer cells. Prior to entering the breast cancer cell, tamoxifen (T) is
  metabolized in the liver into the two active metabolites, endoxifen and 4-hydroxytamoxifen
  (4-OHT). When these metabolites enter the cell (blue background) they can bind to
  estrogen receptors (ERs), thereby blocking the binding of estrogen. ERs bound to
  tamoxifen then dimerize, enter the nucleus and bind to estrogen response element
  (ERE). However, the necessary coactivators will not be recruited by the ER–tamoxifen
  complex. Only corepressors are recruited, therefore gene transcription is not activated.
  In tamoxifen resistance, this blocking is compromised due to several possible mechanisms:
  e.g., changes in activity of the metabolizing enzymes of tamoxifen, loss or modification
  of ER expression, alternative signaling pathways for proliferation and growth, and
  alterations in the balance of co-regulatory proteins and altered expression of microRNAs
  [,]. Black arrow: normal estrogen pathway. Blue arrow: tamoxifen pathway. Crossed
  arrow: disrupted pathway.'
pmcid: PMC4632748
papertitle: The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment
  in Breast Cancer Patients.
reftext: Nina G. Egeland, et al. Int J Mol Sci. 2015 Oct;16(10):24243-24275.
pmc_ranked_result_index: '2721'
pathway_score: 0.9446953
filename: ijms-16-24243-g003.jpg
figtitle: Tamoxifen pathway and possible mechanisms of endocrine resistance in breast
  cancer cells
year: '2015'
organisms:
- Mus musculus
- Sequoia sempervirens
- Homo sapiens
ndex: 96357a41-dee7-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4632748__ijms-16-24243-g003.html
  '@type': Dataset
  description: 'The tamoxifen pathway and possible mechanisms of endocrine resistance
    in breast cancer cells. Prior to entering the breast cancer cell, tamoxifen (T)
    is metabolized in the liver into the two active metabolites, endoxifen and 4-hydroxytamoxifen
    (4-OHT). When these metabolites enter the cell (blue background) they can bind
    to estrogen receptors (ERs), thereby blocking the binding of estrogen. ERs bound
    to tamoxifen then dimerize, enter the nucleus and bind to estrogen response element
    (ERE). However, the necessary coactivators will not be recruited by the ER–tamoxifen
    complex. Only corepressors are recruited, therefore gene transcription is not
    activated. In tamoxifen resistance, this blocking is compromised due to several
    possible mechanisms: e.g., changes in activity of the metabolizing enzymes of
    tamoxifen, loss or modification of ER expression, alternative signaling pathways
    for proliferation and growth, and alterations in the balance of co-regulatory
    proteins and altered expression of microRNAs [,]. Black arrow: normal estrogen
    pathway. Blue arrow: tamoxifen pathway. Crossed arrow: disrupted pathway.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R5
  - AKT3
  - MAPK3
  - EGFR
  - AKT1
  - KRAS
  - NRAS
  - SRC
  - MAPK1
  - PIK3R6
  - PIK3R4
  - AKT2
  - PIK3CB
  - ERBB2
  - IGF1R
  - PTK2
  - PIK3CA
  - GPER1
  - PIK3CG
  - PELP1
  - PIK3R3
  - HRAS
  - PIK3CD
  - Cancer
  - Lung cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: EGFR,
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: SRC
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: HER2,IGFR
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2,IGFR
  symbol: IGFR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: GPER
  symbol: GPER
  source: hgnc_prev_symbol
  hgnc_symbol: GPER1
  entrez: '2852'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PELP1
  symbol: PELP1
  source: hgnc_symbol
  hgnc_symbol: PELP1
  entrez: '27043'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC4632748__F3
redirect_from: /figures/PMC4632748__F3
figtype: Figure
---
